CSF3 and Miyoshi myopathy: The proportion of each transcriptionally defined HSPC cluster in healthy allo-donors (mobilized with G-CSF, plerixafor or motixafortide alone) and in patients with MM (mobilized with placebo + G-CSF, plerixafor + G-CSF or motixafortide + G-CSF) was evaluated (Extended Data Fig. 7).